Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors

Clinical Cancer Research

Volumn 4, Issue 11, 1998, Pages 2701-2708

  Korfel, Agnieszka ^a   Scheulen, Max E ^b   Schmoll, Hans Joachim ^c   Gründel, Olaf ^b   Harstrick, Andreas ^b   Knoche, Martin ^c   Fels, Lüder M ^c   Skorzec, Matthias ^b   Bach, Ferdinand ^d   Baumgart, Joachim ^d   Saß, Gretel ^d   Seeber, Sigfried ^b   Thiel, Eckhard ^a   Berdel, Wolfgang E ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d MEDAC GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TITANOCENE DICHLORIDE;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; URINARY EXCRETION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; TITANIUM; TREATMENT OUTCOME;

EID: 0031757390     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Köpf-Maier, P., and Köpf, H. Transition and main group metal cyclopentadienyl complexes: preclinical studies on a series of antitumor agents of different structural type. Structure and Bonding 70, pp. 103-185. Berlin Heidelberg: Springer, 1988.
2. Köpf-Maier, P. The antitumor activity of transition and main-group metal cyclopentadienyl complexes. Progress in Clinical Biochemistry and Medicine, Vol. 10, pp. 151-184. Berlin Heidelberg: Springer, 1989.
3. Harstrick, A., Schmoll, H-J., Sass, G., Poliwoda, H., and Rustum, Y. M. Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines. Eur. J. Cancer, 29A: 1000-1002, 1993.
4. Harstrick, A., Scheulen, M. E., Rustum, Y., Schmoll, H-J., and Seeber, S. Aktivität von Titanocendichlorid in cisplatin-und doxorubicinresistenten humanen Karzinomzellinien in vitro und in vivo. In: W. E. Berdel, J. Baumgart, and F. Bach (eds.), Titanocenedichlorid, pp. 25-33. München: Zuckschwerdt, 1995.
5. Christodoulou, C. V., Eliopoulos, A. G., Young, L. S., Hodgkins, L., Ferry, D. R., and Kerr, D. J. Anti-proliferative activity and mechanism of action of titanocenedichloride. Br. J. Cancer, 77: 2088-2097, 1988.
6. Köpf-Maier, P. Tumor inhibition by titanocene complexes: influence on xenografted human adenocarcinoma of the gastrointestinal tract. Cancer Chemother. Pharmacol., 23: 225-230, 1989.
7. Cao, S., Durrani, F. A., Baumgart, J., Sass, G., and Rustum, Y. M. Titanocene dichloride - a new organometallic compound, active in vivo against varieties of human tumors with differential sensitivity to doxorubicin and cisplatin. Proc. Am. Assoc. Cancer Res. Annu. Meet., 36: 391, 1995.
8. Köpf-Maier, P., and Gerlach, S. Pattern of toxicity by titanocene dichloride in mice. J. Cancer Res. Clin. Oncol., 111: 243-247, 1986.
9. Köpf-Maier, P. The organ toxicity of the antitumor agent titanocene dichloride is dependent on the route and schedule of application. 9. (Abstract). National Cancer Institute-EORTC Symposium on New Drugs in Cancer Therapy, 1996.
10. Köpf-Maier, P., and Gerlach, S. Pattern of toxicity by titanocene dichloride in mice: hematologic parameters. Anticancer Res., 6: 235-240, 1986.
11. Döppert, K. Die Chemie der Cyclopentadienyl (IV)-Verbindungen in wäßrigem Medium. Naturwissenschaften, 77: 19-24, 1990.
12. Köpf-Maier, P., and Köpf, H. Tumorhemmende Cyclopentadienylmetall-Komplexe. Experimentelle Untersuchungen zur Überprüfung der Cyclopentadien-Hypothese. J. Organometal. Chem., 342: 167-176, 1988.
13. Berdel, W. E., Schmoll, H-J., Scheulen, M. E., Korfel, A., Gründel, O., Harstrick, A., Bach, F., Baumgart, J., and Sass, G. Phase I clinical and pharmacological study of titanocene dichloride in advanced solid tumors (Abstract). American Society of Clinical Oncology Annual Meeting, 1995.
14. Heinzel, G., Woloszczak, R., and Thomann, P. TopFit 2.0 - Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Stuttgart: Fischer, 1993.
15. Bradford, M. M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem., 72: 248-254, 1976.
16. Maruhn, D. Rapid colorimetric assay of β-galactosidase and N-acetyl-β-D-glucosaminidase in human urine. Clin. Chim. Acta, 34: 453-461, 1976.
17. Ward, J. M., and Fauwie, K. A. The nephrotoxic effects of cis-diamminedichloroplatinum (II) (NSC-119875) in male F344 rats. Toxicol. Appl. Pharmacol., 38: 535-547, 1976.
18. Brichard, S. M., Lederer, J., and Henquin, J. C. The insulin-like properties of vanadium: a curiosity or a perspective for the treatment of diabetes? Diabetes Metab., 17:: 435-440, 1991.
19. Belt, R. J., Himmelstein, K. J., Patton, T. F., Bannister, S. J., Sternson, L. A., and Repta, A. J. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichloroammineplatinum (II). Cancer Treat. Rep., 63: 1515-1521, 1979.
20. Himmelstein, K. J., Patton, T. F., Belt, R. J., Taylor, S., Repta, A. J., and Sternson, L. A. Clinical kinetics of intact cisplatin and some related species. Clin. Pharmacol. Ther., 29: 658-664, 1981.
21. Köpf-Maier, P., and Köpf, H. Metallocene complexes: organometallic antitumor agents. Drugs Future, 11: 297-319, 1986.